-
公开(公告)号：US09540334B2
公开(公告)日：2017-01-10
申请号：US14812829
申请日：2015-07-29
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , A61K31/505 , A61K31/519 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D498/04 , C07D265/36 , A61K31/5395 , C07D495/04 , C07F5/02 , C07D498/14 , C07D407/14
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US09248132B2
公开(公告)日：2016-02-02
申请号：US14250329
申请日：2014-04-10
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Yan Chen , Vanessa Taylor , Hui Li , Rajinder Singh
IPC: C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00 , A61K31/5415 , C07D401/14 , C07D403/12 , C07D413/04 , C07D487/08 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/551 , A61K45/06 , C07D413/12 , C07D419/14 , C07D471/08 , C07D487/04 , C07D491/08 , A61K31/538 , A61K31/55 , A61K31/675 , C07D413/14 , C07D471/04 , C07D487/10 , C07D498/04 , C07F9/6558
CPC classification number: C07D413/12 , A61K31/155 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/635 , A61K31/675 , A61K45/06 , C07D401/14 , C07D403/12 , C07D413/04 , C07D413/14 , C07D419/14 , C07D451/02 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D498/04 , C07F9/65583
Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
-
公开(公告)号：US20160009660A1
公开(公告)日：2016-01-14
申请号：US14858661
申请日：2015-09-18
Applicant: Rigel Pharmaceuticals, Inc
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US08853397B2
公开(公告)日：2014-10-07
申请号：US13759835
申请日：2013-02-05
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , A61K31/506 , C07D413/12 , C07D401/12 , A61K31/551 , C07D409/12 , C07D409/14 , A61K31/538 , C07D417/12 , A61K31/519 , C07D405/14 , C07D401/14 , C07D403/14 , C07D265/36 , A61K31/5383 , A61K31/505 , A61K45/06 , C07D413/10 , C07D413/14 , A61K31/5377 , C07D498/04 , C07D405/12 , C07D417/14 , C07D403/12
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US08822685B2
公开(公告)日：2014-09-02
申请号：US13961780
申请日：2013-08-07
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , A61K31/505 , C07D405/14 , A61K31/551 , C07D403/12 , C07D409/14 , A61K31/5383 , C07D413/14 , C07D413/10 , A61K31/5377 , C07D405/12 , C07D265/36 , C07D401/14 , C07D498/04 , C07D409/12 , A61K31/519 , C07D401/12 , C07D417/14 , C07D403/14 , C07D413/12 , A61K31/506 , A61K31/538 , C07D417/12 , A61K45/06
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
Patent Agency Ranking
公开(公告)号：US20140011770A1
公开(公告)日：2014-01-09
申请号：US14023158
申请日：2013-09-10
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Yan Chen , Vanessa Taylor , Hui Li , Rajinder Singh
IPC: C07D413/12 , A61K45/06 , C07D403/12 , C07D471/08 , A61K31/5377 , C07F9/6558 , A61K31/675 , C07D487/08 , A61K31/551 , C07D471/04 , C07D413/14 , A61K31/541 , C07D491/08 , C07D487/04 , C07D487/10 , A61K31/54 , C07D419/14 , A61K31/55 , C07D498/04 , A61K31/5383 , A61K31/538 , A61K31/506
CPC classification number: C07D413/12 , A61K31/155 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/635 , A61K31/675 , A61K45/06 , C07D401/14 , C07D403/12 , C07D413/04 , C07D413/14 , C07D419/14 , C07D451/02 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D498/04 , C07F9/65583
Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Abstract translation: 公开了式I的化合物，含有它们的组合物，以及用于化合物和组合物用于治疗JAK途径的调节或JAK激酶，特别是JAK 2和JAK 3的抑制在治疗上有用的条件的方法。
-
公开(公告)号：US20130309228A1
公开(公告)日：2013-11-21
申请号：US13948342
申请日：2013-07-23
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Andy Atuegbu , John Ramphal , Hui Li , Marina Gelman , Jeffrey Clough , Carlos Valdez , Somasekhar Bhamidipati , Sambaiah Thota , Darren McMurtrie
IPC: A61K31/5383 , A61K45/06
CPC classification number: A61K31/5383 , A61K45/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/08 , C07D498/04
Abstract: Disclosed embodiments provide pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.
-
公开(公告)号：US20130142807A1
公开(公告)日：2013-06-06
申请号：US13750632
申请日：2013-01-25
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong
IPC: A61K31/506 , A61K31/505 , C07F7/10 , A61K31/695 , C07D403/12 , C07D401/12 , A61K31/5377 , C07D413/12 , C07D413/14 , A61K31/541 , A61K31/538 , C07D498/04 , A61K31/5383 , A61K39/395 , A61K38/13 , A61K31/436 , A61K31/343 , C07D239/48
CPC classification number: C07D413/12 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/3955 , A61K45/06 , C07D239/42 , C07D239/48 , C07D285/22 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D413/14 , C07D417/12 , C07D498/04 , C07F7/0812 , C07F7/10
Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
-
公开(公告)号：US20200085820A1
公开(公告)日：2020-03-19
申请号：US16691352
申请日：2019-11-21
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: A61K31/505 , A61K31/519 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D239/48 , C07D417/14 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D498/04 , C07D265/36 , A61K31/5395 , C07D495/04 , C07F5/02 , C07D498/14 , C07D407/14
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20190300518A1
公开(公告)日：2019-10-03
申请号：US16444093
申请日：2019-06-18
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Hui Li , Thilo Heckrodt , Yan Chen , Ryan Kelley , Darren McMurtrie , Kin Tso , Vanessa Taylor , Rajinder Singh , Rose Yen , Jack Maung
IPC: C07D413/14 , A61P29/00
Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
-
-
-
-
-
-
-
-
-
Search Results
115
records
(took 0.086 seconds)
